Antibody and T cell responses to Sinopharm/BBIBP-CorV in naive and previously infected individuals in Sri Lanka

  title={Antibody and T cell responses to Sinopharm/BBIBP-CorV in naive and previously infected individuals in Sri Lanka},
  author={Chandima Jeewandara and Inoka Sepali Aberathna and Pradeep Darshana Pushpakumara and Achala Kamaladasa and Dinuka Guruge and Deshni Jayathilaka and Banuri Gunasekara and Shyrar Tanussiya and Heshan Kuruppu and Thushali Ranasinghe and Shashika Dayarathne and Osanda Dissanayake and Nayanathara Gamalath and Dinithi Ekanayake and Mpdj Jayamali and Ayesha M. Wijesinghe and Madushi Dissanayake and Deshan Madusanka and Tibutius T. P. Jayadas and Anushika Mudunkotuwa and Gayasha Somathilake and Michael Harvie and Thashmi Nimasha and Saubhagya Danasekara and Ruwan Wijayamuni and Lisa Schimanski and Tiong K. Tan and Tao Dong and Alain Townsend and Graham S. Ogg and Gathsaurie Neelika Malavige},
Background: As there are limited data of the immunogenicity of the Sinopharm/BBIBP-CorV in different populations, antibody responses against different SARS-CoV-2 variants of concern and T cell responses, we investigated the immunogenicity of the vaccine, in individuals in Sri Lanka. Methods: SARS-CoV-2-specific antibodies were measured in 282 individuals who were seronegative at baseline, and ACE2 receptor blocking antibodies, antibodies to the receptor binding domain (RBD) of the wild type (WT… Expand
Persistence of antibody and T cell responses to the Sinopharm/BBIBP-CorV vaccine in Sri Lankan individuals
Antibody responses declined in all age groups, especially in those >60 years, while T cell responses persisted, and the effect of waning of immunity on hospitalization and severe disease should be assessed by long term efficacy studies. Expand
Scientific rationale for developing potent RBD-based vaccines targeting COVID-19
The data supporting the non-inferiority of RBD as a vaccine immunogen compared to full-length S-protein vaccines with respect to humoral and cellular immune responses against both the prototype pandemic SARS-CoV-2 isolate and emerging variants of concern are reviewed. Expand
SARS-CoV-2 immunity and an overview of the COVID-19 vaccines
The remarkable development of a large number of vaccines against COVID-19 in a very short period of time represents one of the greatest successes of medicine and science in history, and massExpand
Covid-19 vaccines and variants of concern: A review.
The most relevant mutations in the SARS-CoV-2 spike protein are described, VE against VOCs is discussed, and additional effective vaccines are still needed to meet the global demand. Expand
COVID-19 infection among health care workers: Experience in Base Hospital Wathupitiwala,Sri Lanka.
The incidence, demographic characteristics, and risk exposure behavior of HCWs who tested positive for SARS CoV-2 at Base Hospital Wathupitiwala, Sri Lanka were determined and the rate of acquisition of SARS-2 following COVISHIELD/ChAdOx1 nCoV-19 and Sinopharm /BBIBP-CorV vaccines in HCWs were studied. Expand
Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges
The emergence of a novel coronavirus viz., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late 2019 and its subsequent substantial spread produced the coronavirus disease 2019Expand


Antibody and T-cell responses to a single dose of the AZD1222/Covishield vaccine in previously SARS-CoV-2 infected and naive health care workers in Sri Lanka
A single dose of the AZD1222/Covishield vaccine was shown to be highly immunogenic in previously naive individuals inducing antibody levels greater than following natural infection and in infected individuals, a single dose induced very high levels of ACE2 blocking antibodies and antibodies to RBDs of SARS-CoV-2 variants of concern. Expand
SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees
It is shown that some variants can partially escape humoral immunity induced by SARS-CoV-2 infection or BNT162b2 vaccination, but S-specific CD4+ T-cell activation is not affected by the mutations in the B.1.1-1.351 variants. Expand
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Exploratory analyses of the immune responses in adults, aged 18-55 years, up to 8 weeks after vaccination with a single dose of ChAdOx1 nCoV-19 suggest a favorable immune profile induced by this vaccine candidate, supporting the progression of this vaccines candidate to ongoing phase 2/3 trials to assess vaccine efficacy. Expand
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
Data suggest that protection may require low levels of NAbs and might involve other immune effector mechanisms including non-NAbs, T cells and innate immune mechanisms, as well as potent T cell responses. Expand
Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination
Novel mRNA vaccines for SARS-CoV-2 have been authorized for emergency use. Despite their efficacy in clinical trials, data on mRNA vaccine-induced immune responses are mostly limited to serologicalExpand
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
Sera from individuals having received one dose of Pfizer or AstraZeneca vaccines barely inhibited variant Delta, and it was found that variant Delta spread is associated with an escape to antibodies targeting non-RBD and RBD Spike epitopes. Expand
Comparison of two assays to detect IgG antibodies to the receptor binding domain of SARS‑CoV‑2 as a surrogate marker for assessing neutralizing antibodies in COVID-19 patients
The HAT is a simple, and very cheap assay to perform, it would be ideal to use as an indicator of NAbs in resource-poor settings and the sensitivity and persistence of antibodies in patients with varying severity of illness is assessed. Expand
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.
Therefore, faster-spreading SARS-CoV-2 variants acquired a partial resistance to neutralizing antibodies generated by natural infection or vaccination, which was most frequently detected in individuals with low antibody levels. Expand
A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction
A blocking assay based on the recombinant receptor-binding domain of SARS-CoV-2 spike protein and human angiotensin-converting enzyme 2 receptor provides an alternative to conventional antibody neutralization assays requiring live virus. Expand
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
Two-dose immunizations using 2 μg/dose of BBIBP-CorV provided highly efficient protection against SARS-CoV-2 intratracheal challenge in rhesus macaques, without detectable antibody-dependent enhancement of infection. Expand